impact factor
logo
 

One year in review

 

One year in review 2018: systemic vasculitis


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

 

  1. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  2. Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital 'Santa Maria della Misericordia', Udine, Italy
  3. Department of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
  4. Department of Clinical and Experimental Medicine, Division of Rheumatology, University of Florence, AOUC, Florence, Italy.
  5. Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital 'Santa Maria della Misericordia', Udine, Italy.
  6. Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Italy.
  7. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  8. Ophthalmology Unit, Department of Surgical, Medical, Molecular Pathology and Emergency, University of Pisa, Italy.
  9. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  10. Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital 'Santa Maria della Misericordia', Udine, Italy.
  11. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. chiara.baldini74@gmail.com

CER11381
2018 Vol.36, N°2 ,Suppl.111
PI 0012, PF 0032
One year in review

Free to view
(click on article PDF icon to read the article)

PMID: 29799395 [PubMed]

Received: 06/05/2018
Accepted : 07/05/2018
In Press: 18/05/2018
Published: 18/05/2018

Abstract

Systemic vasculitis are heterogeneous, complex and disabling disorders. Following the previous annual reviews of this series, this paper gives a brief overview on current knowledge about recent literature on small- and large-vessel systemic vasculitis, with a specific focus on pathogenetic and clinical aspects, novel possible disease-related biomarkers and current and future therapies that are in the pipeline.

Rheumatology Article